Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
-$0.02 today
- Market cap
- $110.83M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
Volume 0.07M
Average 0.07M
Returns on capital
Armata Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
79.5%
avg -56.1%
ROIC
-43.1%
avg -75.1%
ROA
-226.1%
avg -76.4%
Analysis
ROE is currently the strongest return metric at 79.5% versus its period average of -56.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Deborah L. Birx | Chief Executive Officer & Director | USD 851.91K | 69 | — | — |
Pierre Kyme | Chief Business Officer | USD 625.75K | 48 | 9.46K | 0.03% |
David House | Chief Financial Officer | USD 513.31K | 42 | — | — |
Peter Hubbard | Vice President of Operations | — | — | — | — |
Bani Tchekanova | Head of Regulatory Strategy & Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -3.8% | +63.0% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -3.8% over three years. Forward estimates point to Revenue at +63.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Armata Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ARMP's management, answered from reported figures.
Who manages ARMP?
Armata Pharmaceuticals, Inc. (ARMP) lists 5 active executives. The top listed executive is Deborah L. Birx, Chief Executive Officer & Director.
Are ARMP insiders buying or selling?
Recent insider activity shows net buying of $195.79M.
Continue the stock analysis
Jump to another research area for this company.